The Leucegene RNA sequencing dataset (691 AML samples) is available in the Gene Expression Omnibus repository (GEO accession number GSE232130). Non-identifiable clinical data for the Leucegene cohort are available to […]
Leucegene data availability statement The datasets generated by the Leucegene project are only partially accessible to the public due to legal and ethical limitations. We understand the importance of data […]
Click on Guy Sauvageau’s interview last october on why should we target RUNX1 in AML treatment.
Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting is now available in Applied Health Economics and Health Policy.
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations is now published in Blood.
Maiga et al. a publié Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets dans la revue scientifique Blood Cancer Journal.
Lemieux et al. a publié MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets dans la revue scientifique Nucleic Acids Research.